Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:56:10 EDT Wed 28 Oct 2026
Enter Symbol
or Name
USA
CA



Q:MNOV - MEDICINOVA INC - https://www.medicinova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNOV - Q0.11.30·2.150.11.41+0.010.737.8462531.42  1.42  1.393.8999  1.168Oct 27Oct 1215 min RT 2¢

Recent Trades - Last 10 of 253
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-12 06:00U:MNOVNews ReleaseMediciNova CEO Provides Shareholder Update
2026-10-06 06:00U:MNOVNews ReleaseMediciNova to Participate in the Maxim Growth Summit
2026-09-28 06:00U:MNOVNews ReleaseMediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-09-24 06:00U:MNOVNews ReleaseMediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
2026-09-08 06:00U:MNOVNews ReleaseMediciNova to Participate in Two Investor Conferences in September
2026-07-15 08:00U:MNOVNews ReleaseMediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients
2026-06-30 08:00U:MNOVNews ReleaseMediciNova CEO Provides Shareholder Update
2026-06-08 08:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
2026-05-26 19:00U:MNOVNews ReleaseMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-04-27 19:00U:MNOVNews ReleaseNew Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
2026-03-16 07:00U:MNOVNews ReleaseMediciNova to Participate at the 38th Annual ROTH Conference
2026-01-29 18:00U:MNOVNews ReleaseMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
2026-01-06 09:00U:MNOVNews Release2026 New Year's Greetings from the CEO
2025-12-18 06:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
2025-12-08 06:00U:MNOVNews ReleaseMediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
2025-12-01 18:00U:MNOVNews ReleaseMessage from the CEO to MediciNova Shareholders
2025-11-18 06:00U:MNOVNews ReleaseMediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
2025-11-06 18:00U:MNOVNews ReleaseMediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
2025-11-04 07:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2025-10-30 19:00U:MNOVNews ReleaseMediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication